Achilles Therapeutics Selects Netrality's 401 North Broad for United States Headquarters
PHILADELPHIA, March 01, 2022 (GLOBE NEWSWIRE) -- Netrality announced today that Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, has leased 7,243 SF of lab space at 401 North Broad. Achilles Therapeutics is developing novel cancer immunotherapies targeting clonal neoantigens: protein markers that are expressed on every cancer cell's surface. Achilles uses DNA sequencing data from each patient and a proprietary bioinformatics platform to identify clonal neoantigens specific to that patient to enable the development of personalized cell therapies. The new lab space within 401 North Broad will s
